Coya Therapeutics (COYA) Non-Current Assets (2021 - 2026)
Coya Therapeutics (COYA) reported Non-Current Assets of $8420.0 for Q1 2026, down 73.48% on a YoY basis from $31748.0 in Q1 2025, and down 25.0% sequentially from $11227.0 in Q4 2025.
Coya Therapeutics (COYA) Non-Current Assets (2021 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 6 years of Non-Current Assets data on file, last reported at $8420.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 73.48% year-over-year to $8420.0; the trailing twelve-month figure through Mar 2026 stood at $62623.0 (down 62.73% YoY), and the FY2025 full-year result was $11227.0, down 70.91% from the prior year.
- Non-Current Assets slipped to $8420.0 in Q1 2026, from $11227.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.2 million in Q4 2022 to a low of $8420.0 in Q1 2026.
- A 5-year average of $128943.2 and a median of $48849.0 in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 482.43% in 2022 and plunged 94.55% in 2023, its largest moves.
- Tracing COYA's Non-Current Assets over 5 years: stood at $1.2 million in 2022, then sank by 94.55% to $65949.0 in 2023, then sank by 41.49% to $38588.0 in 2024, then sank by 70.91% to $11227.0 in 2025, then fell by 25.0% to $8420.0 in 2026.
- Business Quant data shows COYA's Non-Current Assets at $8420.0 in Q1 2026, $11227.0 in Q4 2025, and $18068.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Coya Therapeutics | 97.60 Mn | 46.87 Mn | - | 8,420.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,420.00 |
| Dec 31, 2025 | 11,227.00 |
| Sep 30, 2025 | 18,068.00 |
| Jun 30, 2025 | 24,908.00 |
| Mar 31, 2025 | 31,748.00 |
| Dec 31, 2024 | 38,588.00 |
| Sep 30, 2024 | 45,429.00 |
| Jun 30, 2024 | 52,269.00 |
| Mar 31, 2024 | 59,109.00 |
| Dec 31, 2023 | 65,949.00 |
| Sep 30, 2023 | 72,790.00 |
| Jun 30, 2023 | 79,630.00 |
| Mar 31, 2023 | 86,470.00 |
| Dec 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 207,852.00 |